The listing below shows our latest News Items and is updated regularly. If you wish to post a news item please select the 'Post News' button on the right. The displayed news feed starts on 1st August 2016. Older items can be found here.
To 'Post Your News' use the button at the top right.
We are pleased to present below all posts archived in 'October, 2018'. If you still can't find what you are looking for, try using the search box.
The Biosphere will provide a home for ambitious companies within life sciences and innovation, research and development. The new 90,000 sq. ft purpose-built £25m facility will contain both commercial laboratory and office spaces. As well as satisfying commercial laboratory demand, a conferencing facility for up to 80 people will offer a space for an events programme and for the sector to meet and share knowledge. The building is due for completion late November 2018.
Read the rest of entry »
The ERA Consulting Group (ERA) and Hybrid Concepts International (HCI) announced on 8 October that they have entered into a collaboration agreement in order to more efficiently and effectively support global clients in response to the growing global demand for strategic regulatory support for companies developing cell and gene therapy products, regenerative medicines, and other advanced therapies.
CPI is working alongside Cobra Biologics and GE Healthcare Life Sciences on a project to support the development of cost-effective regenerative medicines.
The three-way partnership, funded by a £570,000 Innovate UK grant, aims to increase the robustness and reduce costs for the manufacturing of adeno-associated virus (AAV) vectors, a delivery vehicle used for emerging gene therapy treatments.
Isansys Lifecare is delighted to announce it has been selected by ConnectTVT as one of the Thames Valley’s 50 Game Changers for 2018. Now in its third year, the programme brings together the region’s most disruptive and fastest-growing digital and tech businesses.
Synpromics is pleased to announce positive data presented on 18 October by a key partner, uniQure (NASDAQ:QURE), at the European Society of Gene and Cell Therapy conference in Lausanne, Switzerland. The study used uniQure’s next-generation liver-directed gene therapy system that incorporates a short, highly-selective and powerful liver promoter that was developed by Synpromics.
AMSBIO has added an important new product to its immunotherapy range - a PD-L2 / TCR activator - CHO Recombinant Cell Line. PD-L2 is one of the key players in immune checkpoint therapy, which is the focus of the 2018 Nobel Prize for Physiology & Medicine . This work pioneered by Professor James P Allison from the USA and Professor Tasuku Honjo from Japan, has led to treatments for cancers, such as melanoma, lung cancer and others based upon immune checkpoint therapy
Synpromics is today unveiling its novel drug-regulatable promoter platform at the European Society of Cell and Gene Therapy (ESGCT) congress in Lausanne, Switzerland. The company is showcasing data generated from its innovative liver inducible and repressible synthetic promoter systems that are tightly controlled by FDA-approved small molecule drugs.
The OBN Annual Awards celebrates the achievements of the UK life sciences industry.
HistologiX Ltd, a leading GLP/GCP compliant IHC and Histology lab, has been acquired by The Intelligent Tissue Group Ltd, joining Tissue Solutions Ltd, world leaders in human tissue provision, to provide a comprehensive integrated range of tissue related CRO services.
ScreenIn3D, a partner of AMSBIO, reports on the accolades it has received following the recent launch of its novel microfluidic cancer screening service. Combining the latest advances in microfluidics and 3D culture - the service uses an optimised screening platform targeted at improving anticancer drug treatment and accelerating development of new personalised medicine solutions.
OBN aims to provide sector NEWS that is relevant to our Membership. We filter information from a variety of sources, publish items ourselves and will publish items of News from our Members. Press releases about OBN can be found here.